Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
This was a phase 2, multicenter, randomized, double-blind, placebo-controlled, open-label comparator study to investigate the efficacy and safety of esaxerenone (CS-3150), a novel non-steroidal mineralocorticoid receptor blocker, in Japanese patients with essential hypertension. Eligible patients (n...
Gardado en:
Main Authors: | , , , , |
---|---|
Formato: | Artigo |
Idioma: | inglés |
Publicado: |
2019
|
Acceso en liña: | https://doi.org/10.1038/s41371-019-0207-x https://www.nature.com/articles/s41371-019-0207-x.pdf |
Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|